Document of opinions and recommendations on type 2 prediabetes

Authors

  • Víctor Francisco Commendatore National University of the Northeast (SAD-UNNE), Corrientes, Argentina
  • Corina Soledad Debiaggi Mains Bleues Clinic, Rafaela, Santa Fe, Argentina
  • Luis Emilio Flores Centro asociado Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CICPBA), La Plata, Provincia de Buenos Aires, Argentina
  • María Natalia Forte CEDIAB-MEPRIN Medical Offices, La Plata, Buenos Aires Province, Argentina
  • Oriana Belén Franceschinis Dr. Eduardo Oller Hospital, Buenos Aires Province, Argentina
  • Gustavo Frechtel University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina
  • Claudio Daniel González "Norberto Quirno" Center for Medical Education and Clinical Research (CEMIC), City of Buenos Aires, Argentina
  • Oscar Gustavo Lorenzo Olascoaga Medical Center (CeDiMCO), Neuquén, Argentina
  • Guillermo Juan Marcucci National University of Cuyo (UnCuyo), Mendoza, Argentina
  • Araceli Antonia Mercado Hecker Esquel Zonal Hospital, Chubut, Argentina
  • María Eugenia Oliva National Scientific and Technical Research Council (FBCB-UNL-CONICET), Santa Fe, Argentina
  • María Belén Redolfi Favaloro Foundation, City of Buenos Aires, Argentina
  • Isaac Sinay Cardiovascular Institute of Buenos Aires, City of Buenos Aires, Argentina
  • Miriam Nora Tonietti Comprehensive Child Health Center, Buenos Aires Province, Argentina
  • Silvina Noemí Valdez National Scientific and Technical Research Council (CONICET)-UBA, City of Buenos Aires, Argentina.

DOI:

https://doi.org/10.47196/diab.v60i2.1361

Keywords:

prediabetes, type 2 diabetes, glycated hemoglobin A1c, impaired fasting glucosa, microvascular complications, macrovascular complications

Abstract

Type 2 prediabetes (T2PD) is a high-prevalence condition that poses a significant public health challenge. Much like type 2 diabetes (T2D), it has an insidious onset and affects millions of individuals worldwide. Beyond its potential progression to T2D, this condition is intrinsically linked to a high risk of developing both macro - and microvascular complications. This suggests that the distinction between T2PD and T2D may currently be based on an arbitrary threshold within the dysglycemia continuum, ranging from normal glucose levels to advanced stages.

We must emphasize the need for early detection and intervention in both pediatric and adult populations, primarily through lifestyle modifications and potentially with pharmacological treatments that have demonstrated efficacy in well-designed studies. Evidence supports that chronic complications and multi-organ involvement can occur from early stages, regardless of whether there is progression to T2D.

Author Biographies

Víctor Francisco Commendatore, National University of the Northeast (SAD-UNNE), Corrientes, Argentina

Director of the Master's Program in Diabetes, Argentine Diabetes Society, Prediabetes Committee

Corina Soledad Debiaggi, Mains Bleues Clinic, Rafaela, Santa Fe, Argentina

Prediabetes Committee of the Argentine Diabetes Society

Luis Emilio Flores, Centro asociado Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CICPBA), La Plata, Provincia de Buenos Aires, Argentina

Center for Experimental and Applied Endocrinology (CENEXA), National University of La Plata–National Scientific and Technical Research Council (UNLP-CONICET), School of Medical Sciences (UNLP), Prediabetes Committee of the Argentine Diabetes Society

María Natalia Forte, CEDIAB-MEPRIN Medical Offices, La Plata, Buenos Aires Province, Argentina

Instructor, Women's Studies Program (Cátedra Libre de la Mujer), National University of La Plata (UNLP); Instructor, University Course, Universidad del Este (UDE), Prediabetes Committee of the Argentine Diabetes Society

Oriana Belén Franceschinis, Dr. Eduardo Oller Hospital, Buenos Aires Province, Argentina

Staff Physician, Diabetes Unit, Prediabetes Committee of the Argentine Diabetes Society

Gustavo Frechtel, University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina

Consultant Professor, Chair of Nutrition, Department of Medicine, School of Medicine; Prediabetes Committee, Argentine Diabetes Society

Claudio Daniel González, "Norberto Quirno" Center for Medical Education and Clinical Research (CEMIC), City of Buenos Aires, Argentina

Department of Pharmacology, Prediabetes Committee of the Argentine Diabetes Society

Oscar Gustavo Lorenzo, Olascoaga Medical Center (CeDiMCO), Neuquén, Argentina

Physician at Olascoaga Medical Center, co-author for the Prediabetes Committee of the Argentine Diabetes Society

Guillermo Juan Marcucci, National University of Cuyo (UnCuyo), Mendoza, Argentina

Professor of Internal Medicine, Prediabetes Committee of the Argentine Diabetes Society

Araceli Antonia Mercado Hecker, Esquel Zonal Hospital, Chubut, Argentina

Outdoor area of ​​Esquel Zonal Hospital, Prediabetes Committee of the Argentine Diabetes Society

María Eugenia Oliva, National Scientific and Technical Research Council (FBCB-UNL-CONICET), Santa Fe, Argentina

Laboratory for the Study of Nutrition-Related Metabolic Diseases (LEEMREN), Faculty of Biochemistry and Biological Sciences, National University of the Litoral; Prediabetes Committee of the Argentine Diabetes Society

María Belén Redolfi, Favaloro Foundation, City of Buenos Aires, Argentina

Staff Physician, Department of Internal Medicine, Churruca-Visca Hospital; Medical Staff, Metabolic Unit; Prediabetes Committee, Argentine Diabetes Society

Isaac Sinay, Cardiovascular Institute of Buenos Aires, City of Buenos Aires, Argentina

Advisor to the Cardiometabolism Unit, Prediabetes Committee of the Argentine Diabetes Society

Miriam Nora Tonietti, Comprehensive Child Health Center, Buenos Aires Province, Argentina

Staff Physician, Comprehensive Child Health Center; Prediabetes Committee, Argentine Diabetes Society

Silvina Noemí Valdez, National Scientific and Technical Research Council (CONICET)-UBA, City of Buenos Aires, Argentina.

Associate Professor, Department of Immunology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires (UBA); Independent Researcher, Prof. Dr. Ricardo A. Margni Institute of Studies on Humoral Immunity (IDEHU), Prediabetes Committee of the Argentine Diabetes Society

References

I. Duncan BB, Magliano DJ, Boyko EJ. EJ. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050. Nephrol Dial Transplant. 2025 Dec 23;41(1):7-9. doi: 10.1093/ndt/gfaf177.

II. Vera-Ponce VJ, Loayza-Castro JA, Zuzunaga-Montoya FE, Sánchez-Tamay NM, et al Prevalence and incidence of prediabetes in Latin America. A systematic review and meta-analysis. J Diabetes Metab Disord. 2024;24(1):25. doi: 10.1007/s40200-024-01549-6.

III. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucosa. Am J Cardiol. 2011;108(3 Suppl):3B-24B. doi: 10.1016/j.amjcard.2011.03.013.

IV. Gabir MM, Hanson RL, Dabelea D, Imperatore G, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care. 2000;23(8):1113-1118. doi: 10.2337/diacare.23.8.1113.

V. Pani LN, Korenda L, Meigs JB, Driver C, et al. Effect of aging on A1C levels in individuals without diabetes. Diabetes Care. 2008;31(10):1991-1996. doi: 10.2337/dc08-0577. doi: 10.47196/diab.v57i1.677.

VI. Maselli M del C, Llanos I, Lucarelli C, Fenili, et al. Hemoglobina A1c. Opiniones y recomendaciones SAD. Rev Soc Arg Diab. 2023;57(1):20-23.

VII. Traverso R, Frechtel G, Bueno R, Rosario C, et al. Convergencias, divergencias, variabilidad, puntos de corte e indicación de la glucemia de ayuno, la hemoglobina glucosilada e insulinemia. Arch Med Int. 2010;32(2-3):41-49.

VIII. Bergman M, Manco M, Satman I, Chan J, et al. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Res Clin Pract. 2024;209:111589. doi: 10.1016/j.diabres.2024.111589.

IX. Rooney M, Wallace AS, Echouffo-Tcheugui JB, Fang M, Hu j, et al. Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes. Diabetologia. 2025;68:357–366. doi: 10.1007/s00125-024-06315-0.

X. Ng HY, Chan LTW. Prediabetes in children and adolescents: an updated review. World J Clin Pediatr. 2023;12(5):263-272. doi: 10.5409/wjcp.v12.i5.263.

XI. Andes LJ, Cheng YJ, Rolka DB, Gregg E, et al. Prevalence of prediabetes among adolescents and young adults in the US, 2005-2016. JAMA Pediatr. 2020;174(2):e194498. doi: 10.1001/jamapediatrics.2019.4498.

XII. Richter B, Hemmingesen B, Metzendorf MI, Takwoingi Y, et al. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018;10(10):Cd012661. doi: 10.1002/14651858.CD012661.pub2.

XIII. Galderisi A, Giannini C, Weiss R, Kim G, et al. Trajectories of changes in glucose tolerance in obese youths: an observational prospective análisis. Lancet Child Adolesc Health 2018;(10):726-735. doi: 10.1016/S2352-4642(18)30235-9.

XIV. Reinehr T, Wolters B, Knop C, Lass N, et al. Strong effect of pubertal status on metabolic health in obese children: a longitudinal study. J Clin Endocrinol Metab. 2015;100(1):301-308. doi: 10.1210/jc.2014-2674.

XV. Lawal Y, Bello F, Kaoje YS. Prediabetes deserves more attention: a review. Clin Diabetes. 2020;38(4):328-338. doi: 10.2337/cd19-0101.

XVI. Rett K, Gottwald-Hostalek U. Understanding prediabetes: definition, prevalence, burden and treatment options for an emerging disease. Curr Med Res Opin. 2019;35(9):1529-1534. doi: 10.1080/03007995.2019.1601455.

XVII. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med. 2016;241:1323-1331. doi: 10.1177/1535370216654227.

XVIII. Wasserman DH, Wang TJ, Brown NJ. The vasculature in prediabetes. Circ Res. 2018;122:1135-1150. doi: 10.1161/CIRCRESAHA.118.311912.

XIX. Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine. 2012;43(3):504-513. doi: 10.1007/s12020-012-9830-9.

XX. Wagner R, Heni M, Tabák AG, Machann J, et al. Pathophysiology-based subphenotyping of individuals at elevated risk for T2D. Nat Med. 2021;27(1):49-57. doi: 10.1038/s41591-020-1116-9.

XXI. Weiss R, Santoro N, Giannini C, Galderisi A, et al. Prediabetes in youth mechanisms and biomarkers. Lancet Child Adolesc Health. 2017;1(3):240-248. doi: 10.1016/S2352-4642(17)30044-5.

XXII. Taksali SE, Caprio S, Dziura J, Dufour S, et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes. 2008;57(2):367-371. doi: 10.2337/db07-0932.

XXIII. Kim G, Bacha F, Tfayli H, Michaliszyn SF, et al. Adipose tissue insulin resistance in youth on the spectrum from normal weight to obese and from normal glucose tolerance to impaired glucose tolerance to type 2 diabetes. Diabetes Care. 2019;42(2):265-272. doi: 10.2337/dc18-1178.

XXIV. American Diabetes Association. Professional Practice Committee 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Suppl 1):S27-S49. doi: 10.2337/dc25-S002.

XXV. World Health Organization. Screening for type 2 diabetes. Report of a World Health Organization and International Diabetes Federation meeting. WHO/NMH/MNC/03.1. Geneva; 2003. Disponible en: https://www.paho.org/sites/default/files/WHO-Screening-Type2-Diabetes-2003.pdf.

XXVI. Commendatore V, Faingod C, Femili C, Frechtel G, et al. Opiniones y recomendaciones de la Sociedad Argentina de Diabetes. Glucemia en ayunas alterada: ¿es oportuno utilizar el punto de corte en 100 mg/dl en Argentina? Rev Soc Arg Diab. 2023;57(1):9-19. doi: 10.47196/diab.v57i1.676.

XXVII. International Expert Committee. Report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-34. doi: 10.2337/dc09-9033.

XXVIII. Shah AS, Barrientos-Pérez M, Chang N, Fu JF, et al. ISPAD Clinical Practice Consensus Guidelines 2024: type 2 diabetes in children and adolescents. Horm Res Paediatr. 2024;97(6):555-583. doi: 10.1159/000543033.

XXIX. Commendatore V, González CD. Frecuencia de prediabetes según glucemia alterada en ayunas, hemoglobina glicada A1c y tolerancia a la glucosa alterada en una población con Finnish Diabetes Risk Score igual o mayor a 13. Un estudio sobre la concordancia diagnóstica (Tesis). UNER; 2025 (a disposición escribiendo a v.commenda@gmail.com).

XXX. Rosas-Guzmán J, Calles J, Friege F, Lara-Esqueda A, et al. Consenso de Prediabetes. Documento de posición de la Asociación Latinoamericana de Diabetes (ALAD) 2009;12(4):146-158. Disponible en: https://www.revistaalad.com/pdfs/0904_ConsPred.pdf.

XXXI. Chaila MZ, Viniegra M, Gagliardino JJ, Lucarello C, et al. Relación entre FINDRISC, glucemia y HbA1c. Rev Soc Arg Diab. 2023;57(2):75-83. doi: 10.47196/diab.v57i2.624.

XXXII. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes care. 2003;26(3):725-731. doi: 10.2337/diacare.26.3.725.

XXXIII. Sacks DB, Arnold M, Bakris GL, Bruns DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes care. 2023;46(10):e151-e199. doi:10.2337/dc23-0036.

XXXIV. US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, et al. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(8):736-743. doi:10.1001/jama.2021.12531.

XXXV. Zand A, Ibrahin K, Patham B. Prediabetes: Why should we care? Methodist Debakey Cardiovasc J. 2018;14(4):289-297. doi: 10.14797/mdcj-14-4-289.

XXXVI. Díaz M. Intolerancia a la glucosa, ¿marcador temprano de daño vascular en pacientes hipertensos? Rev Arg Cardiol. 2005;73(6):412-413. doi: 10.7775/rac.v73i6.2674.

XXXVII. Garber AJ. Hypertension and lipid management in prediabetic states. J Clin Hypertens. 2011;13(4):270-274. doi: 10.1111/j.1751-7176.2011.00451.x.

XXXVIII. Houssay S. Macrovasculopatía y prediabetes. Rev Soc Arg Diab. 2023;57(3). doi: 10.47196/diab.v57i3Sup.666.

XXXIX. Rooney MR, Rawlings AM, Pankows JS, Echouffo-Tcheugio JB, et al. Risk of progression to diabetes among older adults ith prediabetes. JAMA Int Med. 2021;181(4):511-519. doi: 10.1001/jamainternmed.2020.8774. Erratum in: JAMA Intern Med. 2021 Apr 1;181(4):570. doi: 10.1001/jamainternmed.2021.1321.

XL. Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention. Identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019 Apr;42(4):601-608. doi: 10.2337/dc18-1970.

XLI. DeFronzo RA, Tripathy D, Schwnke DC, Banerji M, et al; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucosa tolerance. N Engl J Med. 2011;364:1104-1115. doi: 10.1056/NEJMoa1010949. Erratum in: N Engl J Med. 2011 Jul 14;365(2):189. Erratum in: N Engl J Med. 2011 Sep 1;365(9):869.

XLII. Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, et al; IRIS Investigators. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol 2019;76(5):526-535. doi: 10.1001/jamaneurol.2019.0079. Erratum in: JAMA Neurol. 2019 May 1;76(5):625-626. doi: 10.1001/jamaneurol.2019.0475.

XLIII. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of T2D with lifestyle or metformin. N Engl J Med. 2002;346:393-403. doi: 10.1056/NEJMoa012512.

XLIV. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50. doi: 10.1056/NEJM200105033441801.

XLV. McGowan BM, Bruun JM, Capehorn M, Pedersen SD, et al; STEP 10 Study Group. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;(9):631-642. doi: 10.1016/S2213-8587(24)00182-7

XLVI. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, et al; SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med6;392(10):958-971. doi: 10.1056/NEJMoa2410819.

XLVII. Jongs N, Greene T, Chertow GM, McMurray JJV, et al; DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6

XLVIII. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, et al; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 202;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7

XLIX. The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 12;388(2):117-127. doi: 10.1056/NEJMoa2204233.

L. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8.

LI. Tsai WC, Hsu SP, Chiu YL, Yang JY, et al. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2022;12(10):e060655. doi: 10.1136/bmjopen-2021-060655.

LII. Calderón-Montero A. Evidencias de los iSGLT2 en el tratamiento de la enfermedad renal crónica. Semergen. 2023;49(Suppl 1):102019. doi:10.1016/j.semerg.2023.102019.

LIII. Inzucchi SE, Docherty KF, Køber L, Kosiborod MN, et al; DAPA-HF Investigators and Committees. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care. 2021;44(2):586-594. doi: 10.2337/dc20-1675.

LIV. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi: 10.1056/NEJMoa1911303.

LV. Anker SD, Butler J, Filippatos G, Ferreira JP, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi: 10.1056/NEJMoa2107038.

LVI. Anders HJ, Peired AJ, Romagnani P. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, 'diabetic nephropathy', IgA nephropathy and podocytopathies with FSGS lesions. Nephrol Dial Transplant. 2022 Aug 22;37(9):1609-1615. doi: 10.1093/ndt/gfaa329.

LVII. Butt JH, Jhund PS, Henderson AD, Claggett BL, et al; FINEARTS-HF Committees and Investigators. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes Endocrinol. 2025;13(2):107-118. doi: 10.1016/S2213-8587(24)00309-7.

LVIII. Neves JS, Newman C, Bostrom JA, Buysschaert M, et al. Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Res Clin Pract. 2022;190:109980. doi: 10.1016/j.diabres.2022.109980.

LIX. Hyassat D, Al-Saeksaek S, Naji D, Mahasneh A, et al. Dyslipidemia among patients with type 2 diabetes in Jordan: Prevalence, pattern, and associated factors. Front Public Health. 2022;10:1002466. doi: 10.3389/fpubh.2022.1002466.

LX. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73(4):327-39. doi: 10.1007/s40265-013-0023-5.

LXI. Mehta RK, Koirala P, Mallick RL, Parajuli S, et al. Dyslipidemia in patients with type 2 siabetes mellitus in a tertiary care centre: a descriptive cross-sectional study. JNMA J Nepal Med Assoc. 2021;59(236):305-309. doi: 10.31729/jnma.6278.

LXII. Li J, Nie Z, Ge Z, Shi L, Gao B, et al. Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in Northwest China: a cross-sectional study. Lipids Health Dis. 2022;21(1):77. doi: 10.1186/s12944-022-01691-1.

LXIII. Halcox JP, Banegas JR, Roy C, Dallongeville J, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17(1):160. doi: 10.1186/s12872-017-0591-5.

LXIV. Núñez-Cortés JM, Pedro-Botet J. Atherogenic dyslipemia: the other pandemic, associated with diabesity. Clin Investig Arterioscler. 2021;33(1):30-32. doi: 10.1016/j.arteri.2020.12.001.

LXV. Yu HJ, Ho M, Liu X, Yang J, et al. Association of weight status and the risks of diabetes in adults: a systematic review and meta-analysis of prospective cohort studies. Int J Obes (Lond). 2022;46(6):1101-1113. doi: 10.1038/s41366-022-01096-1.

LXVI. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150-9. doi: 10.1001/2012.jama.11132.

LXVII. Jayedi A, Soltani S, Motlagh SZ, Emadi A, et al. Anthropometric and adiposity indicators and risk of type 2 diabetes: systematic review and dose-response meta-analysis of cohort studies. BMJ. 2022;376:e067516. doi: 10.1136/bmj-2021-067516.

LXVIII. Scilletta S, Welsh P, Di Pino A, Sattar N. Progressive increases in adiposity and ectopic fat surrogates across glycaemic states highlight weight reduction as a key target for type 2 diabetes prevention, especially in younger people. Diabetes Obes Metab. 2026;28(1):654-662. doi: 10.1111/dom.70248.

LXIX. Zhu X, Yang Z, He Z, Hu J, et al. Factors correlated with targeted prevention for prediabetes classified by impaired fasting glucose, impaired glucose tolerance, and elevated HbA1c: A population-based longitudinal study. Front Endocrinol (Lausanne). 2022;13:965890. doi: 10.3389/fendo.2022.965890.

LXX. Nitecki M, Gerstein HC, Balmakov Y, Tsur E, et al. High BMI and the risk for incident type 1 Diabetes Mellitus: a systematic review and meta-analysis of aggregated cohort studies. Cardiovasc Diabetol. 2023;22(1):300. doi: 10.1186/s12933-023-02007-y.

LXXI. Nabila S, Kim JE, Choi J, Park J, et al. Associations between modifiable risk factors and changes in glycemic status among individuals with prediabetes. Diabetes Care. 2023;46(3):535-543. doi: 10.2337/dc22-1042.

LXXII. Luo B, Xu W, Luo F, Zhang S, et al. Association between elevated glycosylated hemoglobin levels and hypertension among US adults: NHANES 2011-2018. BMC Cardiovasc Disord. 2025;25(1):58. doi: 10.1186/s12872-025-04503-3.

LXXIII. Nabila S, Kim JE, Choi J, Park J, et al. Associations between modifiable risk factors and changes in glycemic status among individuals with prediabetes. Diabetes Care. 2023;46(3):535-543. doi: 10.2337/dc22-1042.

LXXIV. Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-1082. doi: 10.2337/dci24-0094.

LXXV. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031.

LXXVI. Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, et al. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol. 2021;34(3):404-414. doi: 10.20524/aog.2021.0604.

LXXVII. Li Y, Yang P, Ye J, Xu Q, et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117. doi: 10.1186/s12944-024-02108-x.

LXXVIII. Park JH, Hong JY, Han K, Shen JJ, et al. Prediabetes remission and the subsequent risk of pancreatic cancer: A nationwide cohort study. Am J Prev Med. 2026;70(1):107979. doi: 10.1016/j.amepre.2025.107979.

LXXIX. Wang N, Zhao TY, Ma X. Increased colorectal cancer risk in prediabetes: A meta-analysis. World J Diabetes. 2025;16(5):103403. doi: 10.4239/wjd.v16.i5.103403.

LXXX. Keesari PR, Jain A, Ganampet NR, Subhasri GSD, et al. Association between prediabetes and breast cancer: a comprehensive meta-analysis. Breast Cancer Res Treat. 2024;204(1):1-13. doi: 10.1007/s10549-023-07181-x.

LXXXI. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. doi: 10.1016/j.juro.2018.03.115.

LXXXII. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, et al; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-16. doi: 10.1210/jc.2011-2513.

LXXXIII. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036-41. doi: 10.2337/diacare.27.5.1036.

LXXXIV. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93(5):1834-40. doi: 10.1210/jc.2007-2177.

LXXXV. Kapoor R, Kapoor A. Erectile dysfunction: a present day coronary disease risk equivalent. Indian J Med Res. 2016;144(3):307-310. doi: 10.4103/0971-5916.198669.

LXXXVI. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6(5):1232-47. doi: 10.1111/j.1743-6109.2008.01168.x.

LXXXVII. Schlesinger S, Neuenschwander M, Barbaresko J, Lang A, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia. 2022;65(2):275-285. doi: 10.1007/s00125-021-05592-3.

LXXXVIII. Lorenzo T, Ngandu T, Lehtisalo J, Antikainen R, et al. Associations of prediabetes, diabetes and glucose-related markers with cognition and neuroimaging in a 2-Year multidomain lifestyle randomised controlled trial. Diabetes Metab Res Rev. 2025;41(5):e70053. doi: 10.1002/dmrr.70053.

LXXXIX. Kapur VK. Obstructive sleep apnea: diagnosis, epidemiology, and economics. Respir Care. 2010;55(9):1155-67.

XC. Kendzerska T, Gershon AS, Hawker G, Tomlinson G, et al. Obstructive sleep apnea and incident diabetes. A historical cohort study. Am J Respir Crit Care Med. 2014;190(2):218-25. doi: 10.1164/rccm.201312-2209OC.

XCI. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015;3(4):310-8. doi: 10.1016/S2213-2600(15)00043-0.

XCII. Peker Y, Hedner J, Norum J, Kraiczi H, et al. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med. 2002;166(2):159-65. doi: 10.1164/rccm.2105124.

XCIII. Sandoval-Rosario M, Nayeri BM, Rascon A, Boring M, et al. Prevalence of arthritis among adults with prediabetes and arthritis-specific barriers to important interventions for prediabetes - United States, 2009-2016. MMWR Morb Mortal Wkly Rep. 2018;67(44):1238-1241. doi: 10.15585/mmwr.mm6744a4.

XCIV. Ursini F, Russo E, D'Angelo S, Arturi F, et al. Prevalence of undiagnosed diabetes in rheumatoid arthritis: an OGTT Study. Medicine (Baltimore). 2016;95(7):e2552. doi: 10.1097/MD.0000000000002552.

XCV. Wan MT, Shin DB, Hubbard RA, Noe MH, et al. Psoriasis and the risk of diabetes. A prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315-322.e1. doi: 10.1016/j.jaad.2017.10.050.

XCVI. Shauly-Aharonov M, Shafrir A, Paltiel O, Calderon-Margalit R, et al. Both high and low pre-infection glucose levels associated with increased risk for severe COVID-19: New insights from a population-based study. PLoS One. 2021;16(7):e0254847. doi: 10.1371/journal.pone.0254847.

XCVII. McAlister FA, Majumdar SR, Blitz S, Rowe BH, et al. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28(4):810-5. doi: 10.2337/diacare.28.4.810.

XCVIII. Wang Q, Fang P, He R, Li M, et al. O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5. Sci Adv. 2020;6(16):eaaz7086. doi: 10.1126/sciadv.aaz7086.

XCIX. Musso C, Mociulsky J, Aranguren F, Debiaggi C, et al. Recomendaciones de vacunación en personas con diabetes en adultos. Opiniones y recomendaciones de la Sociedad Argentina de Diabetes. Rev Soc Arg Diab 2026;60(2).

C. Commendatore V, González CD. Retinopatía diabética en las diferentes categorías glucémicas: normoglucemia, prediabetes y diabetes. Revisión sistemática y metaanálisis (Tesis). Instituto Universitario Barceló. 2026.

CI. Shah VN, Battelino T, Bergenstal RM, Phillip M. Staging prediabetes and type 2 diabetes: the time to start is now. Lancet Diabetes Endocrinol. 2026;14(1):8-10. doi: 10.1016/S2213-8587(25)00333-X.

CII. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011;108(3 Suppl):3B-24B. doi: 10.1016/j.amjcard.2011.03.013.

CIII. Tapp RJ, Zimmet PZ, Harper CA, de Courten MP, et al. AusDiab Study Group. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. Diabetes Res Clin Pract. 2006;73(3):315-21. doi: 10.1016/j.diabres.2006.02.008.

CIV. RAE. Diccionario de la lengua española, Edición del Tricentenario. 2019. Disponible en https://dle.rae.es/

CV. McCance DR, Hanson RL, Charles MA, Jacobsson LT, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308(6940):1323-8. doi: 10.1136/bmj.308.6940.1323.

CVI. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care. 1997;20(5):785-91. doi: 10.2337/diacare.20.5.785.

CVII. Finch CF, Zimmet PZ, Alberti KG. Determining diabetes prevalence: a rational basis for the use of fasting plasma glucose concentrations? Diabet Med. 1990;7(7):603-10. doi: 10.1111/j.1464-5491.1990.tb01457.x.

CVIII. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21(4):518-24. doi: 10.2337/diacare.21.4.518.

Downloads

Published

2026-07-29

Issue

Vol. 60 No. 2 (2026): May–August

Section

Recommendations

License

Copyright (c) 2026 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.